324 related articles for article (PubMed ID: 11599657)
1. Pharmacokinetics of cisplatin and relation to nephrotoxicity in paediatric patients.
Erdlenbruch B; Nier M; Kern W; Hiddemann W; Pekrun A; Lakomek M
Eur J Clin Pharmacol; 2001 Aug; 57(5):393-402. PubMed ID: 11599657
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin nephrotoxicity in children after continuous 72-h and 3x1-h infusions.
Erdlenbruch B; Pekrum A; Roth C; Grunewald RW; Kern W; Lakomek M
Pediatr Nephrol; 2001 Jul; 16(7):586-93. PubMed ID: 11465809
[TBL] [Abstract][Full Text] [Related]
3. Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients.
Nagai N; Kinoshita M; Ogata H; Tsujino D; Wada Y; Someya K; Ohno T; Masuhara K; Tanaka Y; Kato K; Nagai H; Yokoyama A; Kurita Y
Cancer Chemother Pharmacol; 1996; 39(1-2):131-7. PubMed ID: 8995510
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin pharmacokinetics and its nephrotoxicity in diabetic rabbits.
Najjar TA; Saad SY
Chemotherapy; 2001; 47(2):128-35. PubMed ID: 11173815
[TBL] [Abstract][Full Text] [Related]
5. Microalbuminuria during cisplatin therapy: relation with pharmacokinetics and implications for nephroprotection.
Kern W; Braess J; Kaufmann CC; Wilde S; Schleyer E; Hiddemann W
Anticancer Res; 2000; 20(5C):3679-88. PubMed ID: 11268439
[TBL] [Abstract][Full Text] [Related]
6. Application of cisplatin as intraoperative hyperthermic peritoneal lavage (IHPL) in patients with locally advanced gastric cancer: analysis of pharmacokinetics and of nephrotoxicity.
Kern W; Braess J; Kotschofsky M; Samel S; Becker H; Hiddemann W; Schleyer E
Anticancer Res; 2002; 22(5):3099-102. PubMed ID: 12530050
[TBL] [Abstract][Full Text] [Related]
7. Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters.
Lanvers-Kaminsky C; Krefeld B; Dinnesen AG; Deuster D; Seifert E; Würthwein G; Jaehde U; Pieck AC; Boos J
Pediatr Blood Cancer; 2006 Aug; 47(2):183-93. PubMed ID: 16302218
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic determinants of cisplatin-induced subclinical kidney injury in oncology patients.
Ibrahim ME; Chang C; Hu Y; Hogan SL; Mercke N; Gomez M; O'Bryant CL; Bowles DW; George B; Wen X; Buckley B; Aleksunes L; Joy MS
Eur J Clin Pharmacol; 2019 Jan; 75(1):51-57. PubMed ID: 30220072
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin pharmacokinetics in children with cancer.
Peng B; English MW; Boddy AV; Price L; Wyllie R; Pearson AD; Tilby MJ; Newell DR
Eur J Cancer; 1997 Oct; 33(11):1823-8. PubMed ID: 9470840
[TBL] [Abstract][Full Text] [Related]
10. Quantitative relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity in rats: importance of area under the concentration-time curve (AUC) as the major toxicodynamic determinant in vivo.
Nagai N; Ogata H
Cancer Chemother Pharmacol; 1997; 40(1):11-8. PubMed ID: 9137523
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic study of intralesional cisplatin for the treatment of hepatocellular carcinoma.
Mok TS; Kanekal S; Lin XR; Leung TW; Chan AT; Yeo W; Yu S; Chak K; Leavitt R; Johnson P
Cancer; 2001 Jun; 91(12):2369-77. PubMed ID: 11413527
[TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacokinetics of cumulative very high dose of cisplatin in chemotherapy resistant solid tumors.
Tebano MT; Carlini P; Loizzo A; Luzi M; Petrucci F; Alimonti A; Caroli S
Ann Ist Super Sanita; 1995; 31(3):351-7. PubMed ID: 8712579
[TBL] [Abstract][Full Text] [Related]
13. A pharmacokinetic study of high-dose continuous infusion cisplatin in children with solid tumors.
Dominici C; Petrucci F; Caroli S; Alimonti A; Clerico A; Castello MA
J Clin Oncol; 1989 Jan; 7(1):100-7. PubMed ID: 2909663
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin pharmacokinetics and pharmacodynamics in patients with squamous-cell carcinoma of the head/neck or esophagus.
Johnsson A; Höglund P; Grubb A; Cavallin-Ståhl E
Cancer Chemother Pharmacol; 1996; 39(1-2):25-33. PubMed ID: 8995496
[TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin.
Meerum Terwogt JM; Groenewegen G; Pluim D; Maliepaard M; Tibben MM; Huisman A; ten Bokkel Huinink WW; Schot M; Welbank H; Voest EE; Beijnen JH; Schellens JM
Cancer Chemother Pharmacol; 2002 Mar; 49(3):201-10. PubMed ID: 11935212
[TBL] [Abstract][Full Text] [Related]
16. [Relationship between plasma and urinary platinum pharmacokinetics with cisplatin nephrotoxicity in breast cancer patients].
Guo JH
Zhonghua Zhong Liu Za Zhi; 1992 Mar; 14(2):150-3. PubMed ID: 1618086
[TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacokinetics and dose optimisation of carboplatin.
Duffull SB; Robinson BA
Clin Pharmacokinet; 1997 Sep; 33(3):161-83. PubMed ID: 9314610
[TBL] [Abstract][Full Text] [Related]
18. Long-term renal effect of cisplatin in man.
Brillet G; Deray G; Jacquiaud C; Mignot L; Bunker D; Meillet D; Raymond F; Jacobs C
Am J Nephrol; 1994; 14(2):81-4. PubMed ID: 8080010
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic-Pharmacodynamic Analysis of Cisplatin with Hydration and Mannitol Diuresis: The Contribution of Urine Cisplatin Concentration to Nephrotoxicity.
Fukushima K; Okada A; Oe H; Hirasaki M; Hamori M; Nishimura A; Shibata N; Sugioka N
Eur J Drug Metab Pharmacokinet; 2018 Apr; 43(2):193-203. PubMed ID: 28913815
[TBL] [Abstract][Full Text] [Related]
20. Effects of a cisplatin-chondroitin sulfate A complex in reducing the nephrotoxicity of cisplatin.
Zhang JS; Imai T; Otagiri M
Arch Toxicol; 2000 Aug; 74(6):300-7. PubMed ID: 11005675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
